BCL10 and carcinoma: Further in vivo studies are expected to provide a better mechanistic understanding of the CARD14–BCL10–MALT1 axis in PCa and possibly even other carcinomas, eventually opening new therapeutic opportunities for targeting CARD14-mediated signalling in PCa and beyond.